VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated mushroom product developer and research partners with Numinus Wellness Inc., a mental health care company advancing innovative treatments and therapies, have been advised by their clinical trials administrators that they have…


Previous articlePharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
Next articleWhole-Body Effects of Psychedelics – Part 1